Hypopharyngeal Cancer - Pipeline Review, H2 2019
|発行||Global Markets Direct||商品コード||484625|
|出版日||ページ情報||英文 311 Pages
|下咽頭癌治療薬：パイプライン製品の分析 Hypopharyngeal Cancer - Pipeline Review, H2 2019|
|出版日: 2019年11月25日||ページ情報: 英文 311 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2019, provides an overview of the Hypopharyngeal Cancer (Oncology) pipeline landscape.
Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations, the distinction is anatomic rather than pathophysiologic within the group of head and neck malignancies. The hypopharynx is the region between the oropharynx above (at the level of the hyoid bone) and the esophageal inlet below (at the lower end of the cricoid cartilage). Embryologically, the larynx interjects into the hypopharynx anteriorly and is therefore considered a separate structure.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypopharyngeal Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Hypopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.